116 results about "Antidepressant medication" patented technology

The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

The present invention discloses the application of bakuchiol compound in preparing medicine for treating psychogenic diseases and neurogenic diseases. Extracorporeal experiment and animal experiment show that the bakuchiol compound can suppressing dopamine transport protein, noradrenalin transport protein and 5-hydroxy tryptamine transport protein selectively, and no influence on gamma-aminobutyric acid transport protein and L-glytamic acid transport protein, no cytotoxicity, and antidepressant effect higher than available antidepressant medicine amfebutamoe hydrochloride. Therefore, the bakuchiol compound has excellent marketability in preparing medicine for treating psychogenic diseases and neurogenic diseases.

Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, and 4-HNE) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating a subject with depression and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

The invention relates to a 5-HTT gene 13C/T polymorphism site genotype used for forecasting an individual depression sickness degree as well as the sickness degree of the core symptom of the depression, forecasting the effect of an antidepressant as well as the usage, the method and the reagent box of the effect of the antidepressant on the core symptom of the depression; wherein, when the 5-HTT gene 13C/T polymorphism site genotype is of 13TT homozygous type, the individual depression sickness degree and the sickness degree of the core symptom of the depression are forecasted to be more serious; the effect after taking the antidepressant is better; the effect of the antidepressant to the core symptom of the depression is better; when the 5-HTT gene 13C/T polymorphism site genotype is of 13CC homozygous type or 13CT heterozygote type, the individual depression sickness degree and the sickness degree of the core symptom of the depression are forecasted to be lighter; the effect after taking the antidepressant is poorer; the effect of the antidepressant to the core symptom of the depression is poorer.

The invention relates to a medicine for treating post stroke depression and an application thereof. The medicine is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of salvia miltiorrhiza, 25-35 parts of rhizoma acori graminei, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae alba, 10-20 parts of polygala tenuifolia, 5-15 parts of safflower carthamus, 5-15 parts of peach kernel, 7-17 parts of prepared rhizoma cyperi, 5-15 parts of radix bupleuri, 5-15 parts of fructus aurantii, 5-15 parts of radix curcumae, 4-8 parts of pericarpium citri reticulatae viride, 10-20 parts of endothelium corneum gigeriae galli, 25-35 parts of fructus cannabis, 25-35 parts of spina date seed and 25-35 parts of tuber fleeceflower stem. The invention further relates to a composition containing the medicine and fluoxetine hydrochloride. The medicine combined with antidepressant is capable of accelerating the drug effect taking speed, the dose can be controlled, the course of treatment can be shortened, the 'contradictory phenomena' and 'anticholinergic side effect' can be reduced, the effect of the medicine by combining comprehensive rehabilitation therapy is relatively remarkable in the treatment process, and the medicine is capable of gradually replacing the antidepressant in the later period of treatment.

The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.

The invention relates to preparation of a high-purity antidepressant agomelatine and aims to prepare active pharmaceutical ingredients of the agomelatine simply and in large scale. A method is characterized in that 7-methoxytetrahydronaphthalene-1-one (represented as the formula II) is employed as a starting raw material and is reacted with cyanoacetic acid to prepare a compound represented as the formula (III). The compound represented as the formula (III), with the effect of high-purity manganese dioxide, is subjected to dehydrogenation to obtain a compound represented as the formula (IV). The compound represented as the formula (IV) is subjected to hydrogenation reduction and acetylization to obtain a compound represented as the formula (I). The compound represented as the formula (I) is agomelatine. An agomelatine crude product is subjected to purification to obtain high-purity agomelatine.

The invention relates to a long-acting depression relieving microneedle patch and preparation method thereof, and belongs to the technical field of transdermal or transdermal drug delivery preparations. The Long-acting depression relieving microneedle patch is composed of four layers of effective components, including a hydrogel fitting layer for fitting the skin, a degradable microneedle layer for puncturing the skin, a PDMS drug-loading layer serving as a drug storage tank for loading antidepressant drug components, and a waterproof non-woven fabric layer on the outermost layer. The microneedle is made of a biodegradable high polymer material containing calcium carbonate, the strength of the microneedle is effectively enhanced, the puncture performance of the microneedle is improved, and the microneedle can effectively penetrate through the skin cuticle. Amphipathic tetradecanol is used as a slow-release gate valve of a drug storage tank, on one hand, the amphipathic tetradecanol can wrap drugs with different hydrophilic and hydrophobic properties at the same time, and on the other hand, the slow-release performance is good, so that the microneedle patch can achieve the effect of continuously releasing the drugs for a long time. The manufacturing process is simple, the cost is low, and the safety is high.

The invention discloses an HPLC-MS/MS (High Performance Liquid Chromatography-Mass Spectrometry/Mass Spectrometry) method for simultaneously determining the concentrations of 14 antidepressants in human plasma, analytes in a plasma sample are extracted by adopting a protein precipitation method, the sample is separated by adopting an Agilent Infinity Lab Poroshell 120EC-C18 chromatographic column, acetonitrile and water are used as mobile phases for gradient elution, and the mass spectrum condition adopts an electrospray ion source positive ion mode and a multi-ion monitoring mode. The total time of chromatographic separation is 4 minutes. According to the present invention, the 14 antidepressants detected by the method have good linearity (R2 > 0.99) in the blank plasma, the intra-batch and inter-batch precision RSD is 0.65-13.18%, the accuracy is 85.21-117.6%, the matrix effect, the recovery rate, the stability, the dilution effect, the residual effect and the like meet the requirements, and the significant clinical data is provided for the optimization of the clinical drug treatment scheme.

The invention relates to a kit for detecting an antidepressant drug in serum through an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The kit is simple in pretreatment process, low in cost, high in sensitivity and high in specificity, separation and detection of the antidepressant drug are completed within 4.5 min, the accuracy and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antidepressant drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antidepressant drug.

The invention relates to novel 5-alkoxy-tetrazo[1,5-a]qualone compounds, which are represented by a general formula I, and an addition salt formed by the compound and pharmaceutically acceptable acid. The invention also relates to use of the compounds and the addition salt formed by the compounds and the pharmaceutically acceptable acid as antidepressants.

The invention provides a method for preparing a traditional Chinese medicine for curing deficiency in heart and spleen depressive psychosis, and the method belongs to the medical appliance technical field. The depressive psychosis adopts the antidepressant medications for patients with pixilation disease and the imipramine therapy and causes the symptoms such as dry mouth, constipation, sweatiness, fremitus, blurred vision and dysuria. The technical proposal of the invention is as follows: the raw medicines of radix codonopsitis, broiled milk veteh, heterophylly falsestarwort root, atractylis ovata, bidens tripartita, malt extract, Chinese date, tuckahoe, angelica, radix paeoniae alba, lungyen pulp, spina date seed, semen biotae shelled, semen biotae shelled, polygala, cortex albiziae, caulis polygoni multiflori, wheat, ulmaceae, cinnamon and liquorice are placed into 1200 milliliters of water to be steeped for 30 minutes and are decocted by slow fire, the decocted liquid medicine is filtered by gauze to eliminate dregs, and 560 milliliters of liquid medicine which is the traditional Chinese medicine for curing deficiency in heart and spleen depressive psychosis is made. The traditional Chinese medicine has the advantages of simple preparation, fewer side effect and low toxicity. After the medicine is taken orally, the medicine can be absorbed in a digestive canal; therefore, the curative effect is stable and is not easy to rebound.

The invention discloses a method for removing an antidepressant drug in water by activating persulfate. The method comprises the following specific steps: adding ultrapure water and an aqueous solution of antidepressant drug into a 100-ml brown blue-mouth bottle, adding ferrous sulfate heptahydrate and a cysteine solution, adding persulfate, conducting mixing to form a 50-ml reaction system, and conducting reacting at a normal temperature under the condition that the initial concentration of the antidepressant drug is 10 mg/L so as to degrade the antidepressant drug. According to the method, ecological reducing agents Cys, Fe<2+> and persulfate are added into the antidepressant drug solution, and Fe<3+> is converted into Fe<2+> through efficient catalytic conversion of Cys, so sulfate freeradicals and hydroxyl free radicals can be generated by repeatedly utilizing the reaction of Fe<2+> and persulfate, and venlafaxine in water is further oxidized and degraded. The method is simple inprocess flow, does not need complex devices, is mild in reaction conditions, realizes rapid reaction at normal temperature and normal pressure, and is short in reaction time, high in operability and reduced in labor intensity and cost.